评估在接受全关节整形手术的糖尿病患者中使用甲的使用:系统性审查和元分析
Daniel Razick1, Muzammil Akhtar1, Ubaid Ansari1
1College of Medicine, California Northstate University, Elk Grove, California.
The Journal of arthroplasty
|December 20, 2024
概括
在接受关节置换手术的糖尿病患者中使用甲似乎是安全的,在术后第一天,血糖仅略有暂时增加. 需要进一步的研究来确定糖尿病患者的最佳剂量.
科学领域:
- 整形外科手术 整形外科手术
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 美国关节和膝关节外科医生协会建议德克萨米他用于整体关节关节整形手术.
- 由于安全问题,在接受这些手术的糖尿病患者中使用甲是有争议的.
研究的目的:
- 为了确定德克萨米他在接受全关节整形手术的糖尿病患者的安全性.
- 为了计算术后的葡萄糖水平.
- 为了确定一个理想的甲剂量方案.
- 报告与德克萨米他管理相关的并发症.
主要方法:
- 一项对12项研究的元分析,其中包括46685名患者 (23892名接受德克萨米他治疗).
- 干预组和对照组在第一,第二和第三天的术后葡萄糖水平的比较.
- 随机效应的比例在元分析中按研究规模加权.
主要成果:
- 德克萨米他在术后第一天显著提高了平均葡萄糖水平 (170.1 ± 5.3 mg/dL对比158.1 ± 5.8 mg/dL,P = 0.0007),但仍低于200 mg/dL.
- 在术后第二天和第三天,没有观察到葡萄糖水平的显著差异.
- 两组之间感染风险没有显著差异 (RR:0.82,95% CI:0.39-1.72,P = 0.61).
- 由于数据异质性,无法确定理想的甲剂量.
结论:
- 在接受整体关节整形手术的糖尿病患者中,经手术期间使用德克萨米他似乎安全.
- 需要进一步的研究来优化德克萨米他的剂量和时间,以平衡治疗效益和预防高血糖症.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
01:22Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
01:15Diabetes: Management and Pharmacotherapy
244
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
244
01:21Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
227
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
227
01:16Insulin: Dosing Regimen and Adverse Effects
156
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
156